1-4 of 4
James D'Olimpio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3288.
https://doi.org/10.1182/blood-2023-182568
Published: 2023
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D'Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3279.
https://doi.org/10.1182/blood-2023-174096
Published: 2023
Journal Articles

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)

Edwin C. Kingsley, Shannon Fabre, Motohisa Takai, Aileen Cleary Cohen, Jingjing Schneider, Jessica Li, James D'Olimpio
Journal: Blood
Blood (2023) 142 (Supplement 1): 6171.
https://doi.org/10.1182/blood-2023-172881
Published: 2023
Journal Articles

HMGB1 Expression in Sickle Cell Disease: A Pro-Inflammatory Cytokine and Potential Therapeutic Target.

Myra F. Barginear, MD, Anu G. Chandok, MD, Cristina Sison, PhD, Lihong Yang, PhD, Daniel R. Budman, MD, James D’Olimpio, MD, Kevin J. Tracey, MD, Thomas Bradley, MD
Journal: Blood
Blood (2007) 110 (11): 3803.
https://doi.org/10.1182/blood.V110.11.3803.3803
Published: 2007